Related Experiment Videos
Current trials in multiple sclerosis: established evidence and future hopes
Joep Killestein1, Chris H Polman
1Department of Neurology, MS Centre, VU Medical Centre Amsterdam, Amsterdam, The Netherlands.
Current Opinion in Neurology
|May 14, 2005
Summary
Reviewing 2004 multiple sclerosis trials reveals improved use of existing therapies and exciting new treatment options. Advances in understanding pathophysiology are driving innovative therapeutic strategies for multiple sclerosis patients.
Area of Science:
- Neurology
- Immunology
- Clinical Trials
Background:
- Current disease-modifying drugs for multiple sclerosis (MS) show limited effectiveness, particularly in progressive forms.
- Inconvenience and toxicity of existing MS therapies necessitate novel treatment strategies.
- Understanding MS pathophysiology is crucial for developing new treatments.
Purpose of the Study:
- To review multiple sclerosis (MS) therapeutic trials published or presented in 2004.
- To provide an updated overview of established evidence and new insights in MS treatment.
- To highlight advancements in understanding and treating MS.
Main Methods:
- Review of therapeutic trials for multiple sclerosis (MS) from 2004.
- Analysis of published and presented data on MS treatments.
- Synthesis of information on established and emerging MS therapies.
Main Results:
- New data enhance understanding of optimal use for approved disease-modifying drugs in multiple sclerosis (MS).
- A new treatment modality was approved by the US Food and Drug Administration (FDA) for relapsing forms of MS.
- Numerous reports on emerging treatment modalities for MS were published in 2004.
Conclusions:
- Significant advances have been made in multiple sclerosis (MS) treatment.
- Improved knowledge guides the application of existing MS medications.
- Increased insight into MS pathophysiology fuels innovative therapeutic approaches.